Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 16/20 | 0.62 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028258 | 1.00 | CAPN1 (0.62) | CAPN1CTSBCTSSACEOPRM1 | |
| SCHEMBL20027711 | 0.80 | CAPN1 (0.60) | CAPN1CTSBCTSS | |
| SCHEMBL30133614 | 0.80 | CAPN1 (0.60) | CAPN1CTSBCTSS | |
| SCHEMBL20027776 | 0.79 | CAPN1 (0.55) | CAPN1CTSBCTSSOPRM1OPRK1 | |
| SCHEMBL288286 | 0.79 | CAPN1 (0.64) | CAPN1CTSBCTSS | |
| SCHEMBL1612208 | 0.79 | CAPN1 (0.64) | CAPN1CTSBCTSS | |
| SCHEMBL288734 | 0.79 | CAPN1 (0.64) | CAPN1CTSBCTSS | |
| SCHEMBL289625 | 0.77 | CAPN1 (1.00) | CAPN1 | |
| SCHEMBL288543 | 0.77 | CAPN1 (1.00) | CAPN1 | |
| SCHEMBL289000 | 0.77 | CAPN1 (1.00) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885CTSB 105/4885CTSS 210/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | CAPN1 4/4885CTSB 193/4885CTSS 199/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885CTSB 105/4885CTSS 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.